FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development

Seeking Alpha12:52 ET

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?

Zacks Jan 6 07:00 ET

J.P. Morgan Sticks to Its Sell Rating for Roche Holding AG (RHHVF)

TipRanksJan 6 06:06 ET · Ratings

CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.

CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides

Sina Hong Kong StocksJan 3 03:36 ET

Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3

MT NewswiresJan 2 00:10 ET

Innovent Enters Into Exclusive Global License Agreement With Roche for Novel DLL3 Antibody Drug Conjugate

PR NewswireJan 1 18:30 ET